title: [Primary colorectal lymphoma of diffuse large B-cells: an experience at a general hospital].
abstract: Primary colorectal lymphoma is a very rare disease. Primary colorectal lymphoma of diffuse large B-cells is a more frequent subtype representing 1% of all colon diseases. In a retrospective study, the clinical characteristics and treatment course of primary colorectal lymphoma of diffuse large B-cells between 1997 and 2003 were reviewed. According to Dawson's criteria, fourteen cases were identified. The average age was 65 and the ratio of men to women was 1:3. The most frequent signs and symptoms were abdominal pain (78%), diarrhea (49%) and abdominal tumor (35%). The most frequently involved regions were the cecum (42%), ascending colon (21%) and rectum (21%). Six were in Stage I, four in Stage II and four in Stage III. The 5-year survival per stage was 26, 11 and 5 months, respectively. Primary colorectal lymphoma of diffuse large B-cells usually affects the right part of the colon in an aggressive manner.
authors.affiliation: Oncólogo médico, Departamento Oncología Médica-Radioterapia, Hospital Edgardo Rebagliati Martins. bgbrady@hotmail.com
authors.forename: Brady
authors.initials: B
authors.lastname: Beltran Gárate
authors.forename: Domingo
authors.initials: D
authors.lastname: Morales Luna
authors.forename: Pilar
authors.initials: P
authors.lastname: Quiñones Avila
authors.forename: Fernando
authors.initials: F
authors.lastname: Hurtado de Mendoza
authors.forename: Luis
authors.initials: L
authors.lastname: Riva Gonzales
authors.forename: Alejandro
authors.initials: A
authors.lastname: Yabar
authors.forename: Karem
authors.initials: K
authors.lastname: Portugal Meza
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002432:Cecum / Q000473:pathology; D003106:Colon / Q000473:pathology; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D012007:Rectum / Q000473:pathology; D012189:Retrospective Studies; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone